Home > others & > Voglibose

Voglibose

伏格列波糖,AO 128,AO-128,AO128

Voglibose是valiolamine的衍生物，能很好的抑制α-葡萄糖苷酶，可作用于高血糖症等。

目录号
EY0741
EY0741
EY0741
纯度
99.21%
99.21%
99.21%
规格
50 mg
100 mg
200 mg
原价
632.00
928.00
1650.00
售价
632.00
928.00
1650.00
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Chen X, et al. Curr Med Chem, 2006, 13(1), 109-116.
    [2] Moritoh et al (2009) Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J.Pharmacol.Exp.Ther. 329 669
    [3] Matsui et al (2009) α-Glucosidase inhibition assay in an enzyme-immobilized amino-microplate. Anal.Sci. 25 559.
    [4] Matsuo et al (1992) Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am.J.Clin.Nutr. 55 314S.

    分子式
    C10H21NO7    		 分子量
    267.28    		 CAS号
    83480-29-9    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    75 mM    		 Water
    100 mM    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01993927 Impaired Glucose Tolerance Drug: Voglibose Takeda 2009-11-01 2014-07-23
    NCT02049814 Type 2 Diabetes Mellitus Drug: Metformin|Drug: Voglibose|Drug: Acarbose Takeda Phase 4 2014-06-01 2017-02-02
    NCT01055652 Type 2 Diabetes Mellitus Drug: Dapagliflozin AstraZeneca|Bristol-Myers Squibb Phase 1 2010-01-01 2011-10-14
    NCT00663884 Diabetes Mellitus, Type 2 Drug: Mitiglinide|Drug: Voglibose JW Pharmaceutical Phase 4 2008-02-01 2012-03-28
    NCT00654381 Diabetes Mellitus, Type 2 Drug: BI 1356|Drug: BI 1356|Drug: voglibose placebo|Drug: BI 1356 placebo|Drug: voglibose Boehringer Ingelheim Phase 3 2008-04-01 2013-12-11
    NCT00837577 Diabetes Mellitus, Non-Insulin-Dependent Drug: Comparator: Placebo|Drug: Sitagliptin|Drug: Voglibose Merck Sharp & Dohme Corp. Phase 3 2009-02-01 2015-07-16
    NCT01309698 Type 2 Diabetes Drug: Vildagliptin (LAF237)|Drug: Voglibose|Drug: Vildagliptin and Voglibose Novartis Pharmaceuticals|Novartis Phase 4 2011-02-01 2016-11-16
    NCT00411554 Diabetes Mellitus, Non-Insulin-Dependent Drug: sitagliptin phosphate|Drug: Comparator: voglibose Merck Sharp & Dohme Corp. Phase 3 2007-01-01 2016-02-03
    NCT01263509 Type 2 Diabetes Mellitus Drug: Alogliptin and voglibose|Drug: Alogliptin and voglibose Takeda Phase 2|Phase 3 2007-06-01 2012-02-01
    NCT00368134 Diabetes Mellitus, Type 2 Drug: Vildagliptin Novartis Phase 3 2006-08-01 2007-06-27
    NCT00970528 Diabetes Mellitus, Type 2 Drug: Acarbose (Glucobay, BAYG5421)|Drug: Voglibose (Basen) Bayer Phase 4 2009-11-01 2014-02-18
    NCT01263483 Type 2 Diabetes Mellitus Drug: Alogliptin and voglibose|Drug: Alogliptin and voglibose|Drug: Voglibose Takeda Phase 2|Phase 3 2007-01-01 2012-02-01
    NCT02097342 Type 2 Diabetes Mellitus|Insulin Sensitivity/Resistance Drug: Linagliptin|Drug: Placebo|Drug: Voglibose Postgraduate Institute of Medical Education and Research Phase 4 2013-12-01 2014-04-06
    NCT02287402 Impaired Glucose Tolerance (IGT) Drug: AO-128 Takeda Phase 4 2010-03-01 2015-04-08
    NCT00212017 Impaired Glucose Tolerance|Myocardial Infarction Drug: voglibose National Cerebral and Cardiovascular Center 2005-04-01 2007-11-07
    NCT01263496 Type 2 Diabetes Mellitus Drug: Alogliptin|Drug: Alogliptin|Drug: Alogliptin|Drug: Alogliptin|Drug: Voglibose Takeda Phase 2 2007-05-01 2012-02-01
    NCT01242202 Type 2 Diabetes Mellitus Drug: ASP1941|Drug: alpha glucosidase inhibitor Astellas Pharma Inc Phase 3 2010-10-01 2016-01-18
    NCT01263470 Diabetes Mellitus, Type 2 Drug: Alogliptin|Drug: Alogliptin|Drug: Alogliptin|Drug: Alogliptin|Drug: Voglibose|Drug: Placebo Takeda Phase 2 2007-01-01 2012-02-01
    NCT02774759 Malignant Neoplasms of Female Genital Organs Device: Accelerometer|Behavioral: Questionnaires|Behavioral: Fitness Test|Behavioral: Resistance Training|Behavioral: Aerobic Exercise|Behavioral: Telephone Coaching/Phone Calls|Behavioral: Video Chat Sessions M.D. Anderson Cancer Center|National Cancer Institute (NCI) 2016-10-01 2017-02-28
    NCT02194387 Breast Cancer|Ovarian Cancer Behavioral: Telephone Coaching|Behavioral: Text Messaging|Behavioral: Resistance Training|Behavioral: Daily Self-Monitoring|Behavioral: 4 - 7 Days a Week Self-Monitoring|Behavioral: Questionnaires|Behavioral: Email Coaching M.D. Anderson Cancer Center 2014-09-01 2016-12-14
    NCT01682824 Central Nervous System Neoplasms Behavioral: Three-Factor Eating Questionnaire (TFEQ)-R18v2|Behavioral: Multifactor Screener|Behavioral: Eating Questionnaire-EMA (EQ-EMA) M.D. Anderson Cancer Center|Baylor College of Medicine|Texas Children's Cancer Center 2013-05-01 2016-08-16
    NCT01697592 Type 2 Diabetes Mellitus Drug: Omarigliptin|Drug: Matching placebo to omarigliptin Merck Sharp & Dohme Corp. Phase 3 2012-10-01 2016-10-28

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：